Newly published results showed spesolimab significantly improved signs and symptoms of flares in rare, life-threatening skin disease, generalized pustular psoriasis

/PRNewswire/ -- Boehringer Ingelheim announced today the publication in The New England Journal of Medicine of new data from the pivotal Phase II Effisayil™ 1...

Related Keywords

New York ,United States ,Prnewswire Boehringer Ingelheim ,Christopher Wahlers ,Matt Frankel ,Mark Lebwohl ,Boehringer Ingelheim Pharmaceuticals ,Ericj Waldman Department Of Dermatology ,Boehringer Ingelheim Pharmaceuticals Inc ,Boehringer Ingelheim ,Drug Administration ,Icahn School Of Medicine At Mount Sinai ,Animal Health ,Clinical Development ,New England Journal ,Clinical Therapeutics ,Icahn School ,Mount Sinai ,Biologics License Application ,Priority Review ,Orphan Drug Designation ,Breakthrough Therapy Designation ,Vice President ,Medical Affairs ,Specialty Care ,Global Assessment ,Ingelheim Immunology ,Pioneering Science ,Human Pharma ,Biopharmaceutical Contract ,Ingelheim Pharmaceuticals ,